AngioDynamics (ANGO) Upgraded to Strong-Buy at BidaskClub

BidaskClub upgraded shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a strong-buy rating in a research note published on Tuesday.

Several other analysts also recently commented on the stock. Zacks Investment Research raised shares of AngioDynamics from a hold rating to a buy rating and set a $19.00 price objective on the stock in a research report on Monday, January 22nd. Raymond James Financial raised shares of AngioDynamics from a market perform rating to an outperform rating and set a $16.33 price objective on the stock in a research report on Tuesday, April 3rd. TheStreet downgraded shares of AngioDynamics from a b- rating to a c rating in a report on Tuesday, January 2nd. Craig Hallum downgraded shares of AngioDynamics from a buy rating to a hold rating in a report on Friday, January 5th. Finally, UBS raised shares of AngioDynamics from a market perform rating to an outperform rating in a report on Tuesday, April 3rd. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $17.87.

Shares of ANGO stock opened at $19.79 on Tuesday. AngioDynamics has a one year low of $14.80 and a one year high of $20.18. The stock has a market cap of $732.04, a P/E ratio of 27.63, a PEG ratio of 1.79 and a beta of 1.00. The company has a current ratio of 2.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.16.



AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, March 29th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. AngioDynamics had a net margin of 0.97% and a return on equity of 5.11%. The company had revenue of $83.85 million for the quarter, compared to the consensus estimate of $86.13 million. analysts forecast that AngioDynamics will post 0.74 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of AngioDynamics during the 3rd quarter valued at about $143,000. Crossmark Global Holdings Inc. purchased a new stake in shares of AngioDynamics during the 4th quarter valued at about $172,000. Teacher Retirement System of Texas purchased a new stake in shares of AngioDynamics during the 4th quarter valued at about $201,000. MetLife Investment Advisors LLC purchased a new stake in shares of AngioDynamics during the 4th quarter valued at about $297,000. Finally, Texas Yale Capital Corp. purchased a new stake in shares of AngioDynamics during the 4th quarter valued at about $334,000. 97.09% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “AngioDynamics (ANGO) Upgraded to Strong-Buy at BidaskClub” was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/13/angiodynamics-ango-upgraded-to-strong-buy-at-bidaskclub.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply